Major Depressive Disorder Market to Witness Growth by 2032 | Companies-Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Minerva Neurosciences

DelveInsight's "Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Major Depressive Disorder, historical and forecasted epidemiology as well as the Major Depressive Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Major Depressive Disorder market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Major Depressive Disorder market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Major Depressive Disorder treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Major Depressive Disorder market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Major Depressive Disorder: An Overview

Major depressive disorder (MDD), also referred to as depression, is a serious medical illness that disrupts a person's mood, behavior, and thought processes, apart from degrading physical health. It should not be mistaken for the passing feelings of unhappiness that everyone experiences, nor should it be confused with the intense grief brought about by the death of a loved one. Sadness and grief are normal reactions to life stresses. With time, and usually, without medical treatment, sadness and grief lift, and people go on with their lives. By contrast, without specialized medical treatment, depression often persists. But with effective treatment, a large majority of people improve significantly. In most instances, major depressive disorder is a recurrent, episodic illness. This means that a person who has been depressed once and has recovered is likely to have one or more episodes of depression in the future, often within two to three years. When depression is not treated or is treated inappropriately, it is potentially fatal: nearly one in six people with severe, untreated depression commits suicide. However, seeking help and receiving an accurate diagnosis from a psychiatrist or other health care professional is a crucial and often decisive step toward recovery.

Major depressive disorder is one form of depressive illness or mood disorder. Other forms include bipolar disorder (manic-depressive illness) and dysthymia. In bipolar disorder, episodes of depression alternate with episodes of mania, a condition in which inappropriate or extreme "high" feelings may lead to dangerous, destructive behavior. Dysthymia involves symptoms similar to those of major depressive disorder. The symptoms are milder but longer-lasting, and although they might not be disabling, they prevent a person from feeling good or operating at "full steam." Occasionally, a person with dysthymia may also have a major depressive disorder, a condition referred to as double depression.

According to the World Health Organization (WHO), unipolar depression is one of the leading causes of disability-adjusted life year (DALY) and approximately 350 million people worldwide are said to suffer from this mental disorder. As described in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM- V), the hallmark of major depressive disorder is the occurrence of depressed mood (dysphoria) and loss of interest in activities that were rather pleasurable in the past (anhedonia) for a duration of at least two weeks. These symptoms must also be accompanied by at least four of the following manifestations such as changes in appetite or weight, sleep patterns, altered psychomotor activity, feelings of worthlessness or guilt, difficulty concentrating or making decisions, and recurrent thoughts of death or suicidal ideation. Even though there are plenty of drugs developed for the management of depression, one of the challenges in dealing with this disease is that a significant portion of the patients taking antidepressants fails to attain full remission. Some patients also develop treatment-resistant depression in which the patients fail to respond to the available major depressive disorder pipeline drugs or other therapeutic approaches.

More than just a bout of the blues, depression isn't a weakness and you can't simply "snap out" of it. Depression may require long-term treatment. But don't get discouraged. Most people with depression feel better with medication, psychotherapy or both
Learn more about Major Depressive Disorder, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Major Depressive Disorder Market

The Major Depressive Disorder market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Major Depressive Disorder market trends by analyzing the impact of current Major Depressive Disorder therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Major Depressive Disorder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Major Depressive Disorder market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Major Depressive Disorder market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Major Depressive Disorder Epidemiology

The Major Depressive Disorder epidemiology section provides insights into the historical and current Major Depressive Disorder patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Major Depressive Disorder market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Major Depressive Disorder Epidemiology at: https://www.delveinsight.com/report-store/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Major Depressive Disorder Emerging Drugs
To meet the current demands of the patient pool and to counter the major depressive disorder unmet needs of the therapeutic market, drug developers are gradually shifting their attention toward major depressive disorder as a possible indication for new targeted therapies.

Several companies are working robustly on many new therapies, such as AXS-05 (Axsome Therapeutics), Vraylar (AbbVie), Zuranolone (SAGE Therapeutics), and LY03005 (Luye Pharma). The mid-stage pipeline is crowded, with several potential therapies with the imminent attention of big pharmaceutical companies for this market space.

AXS-05 (Axsome Therapeutics), is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development to treat major depressive disorder and other central nervous systems (CNS) disorders. AXS-05 utilizes a proprietary formulation and dose of dextromethorphan and bupropion and Axsome's metabolic inhibition technology to modulate the delivery of the components. The dextromethorphan component of AXS-05 is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, also known as a glutamate receptor modulator, which is a novel mechanism of action, meaning it works differently than currently approved therapies for major depressive disorder. The dextromethorphan component of AXS-05 is also a sigma-1 receptor agonist. The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan and is a norepinephrine and dopamine reuptake inhibitor.

Vraylar (AbbVie) is an oral, once-daily atypical antipsychotic approved for the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder, with a recommended dose range of 3-6 mg/day, and for the treatment of schizophrenia in adults, with a recommended dose range of 1.5-6 mg/day.

While the mechanism of action of Vraylar in schizophrenia and bipolar I disorder is unknown, the efficacy of VRAYLAR could be mediated through a combination of partial agonist activity at central dopamine D and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Pharmacodynamic studies with cariprazine have shown that it acts as a partial agonist with high binding affinity at dopamine D3, dopamine D2, and serotonin 5-HT1A receptors. Cariprazine demonstrated up to ~eightfold greater in vitro affinity for dopamine D3 vs. D2 receptors. Cariprazine also acts as an antagonist at serotonin 5-HT2B and 5-HT2A receptors with high and moderate binding affinity, respectively, as well as it binds to the histamine H1 receptors. Cariprazine shows lower binding affinity to the serotonin 5-HT2C and 1A- adrenergic receptors and has no appreciable affinity for cholinergic muscarinic receptors. The clinical significance of these in vitro data is unknown. The company has announced the submission of the Supplemental New Drug Application to US FDA for cariprazine (Vraylar) for the adjunctive treatment of major depressive disorder.

Major Depressive Disorder Companies
Takeda Pharmaceuticals
Forest Laboratories
Otsuka Pharmaceuticals
Janssen Research & Development
Axsome Therapeutics
AbbVie
SAGE Therapeutics
Minerva Neurosciences
Luye Pharma
Relmada Therapeutics
BioLite Inc.
VistaGen Therapeutics
Praxis Precision Medicines
Intra-Cellular Therapies
Neurocrine Biosciences
Arrivo Bioventures
Sirstei Pharmaceuticals
Alto Neuroscience
Chase Therapeutics
Neumora Therapeutics, Inc.
BlackThorn Therapeutics, Inc.
Otsuka Pharmaceutical Co., Ltd.
Fabre-Kramer Pharmaceuticals
Novartis

Major Depressive Disorder Pipeline Development Activities

The Major Depressive Disorder report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Major Depressive Disorder key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Major Depressive Disorder pipeline development activities at: https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Major Depressive Disorder Therapeutics Assessment

Major key companies are working proactively in the Major Depressive Disorder Therapeutics market to develop novel therapies which will drive the Major Depressive Disorder treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Major Depressive Disorder Report Key Insights

1. Major Depressive Disorder Patient Population
2. Major Depressive Disorder Market Size and Trends
3. Key Cross Competition in the Major Depressive Disorder Market
4. Major Depressive Disorder Market Dynamics (Key Drivers and Barriers)
5. Major Depressive Disorder Market Opportunities
6. Major Depressive Disorder Therapeutic Approaches
7. Major Depressive Disorder Pipeline Analysis
8. Major Depressive Disorder Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Major Depressive Disorder Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Major Depressive Disorder Competitive Intelligence Analysis
4. Major Depressive Disorder Market Overview at a Glance
5. Major Depressive Disorder Disease Background and Overview
6. Major Depressive Disorder Patient Journey
7. Major Depressive Disorder Epidemiology and Patient Population
8. Major Depressive Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Major Depressive Disorder Unmet Needs
10. Key Endpoints of Major Depressive Disorder Treatment
11. Major Depressive Disorder Marketed Products
12. Major Depressive Disorder Emerging Therapies
13. Major Depressive Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Major Depressive Disorder Market Outlook (7 major markets)
16. Major Depressive Disorder Access and Reimbursement Overview
17. KOL Views on the Major Depressive Disorder Market
18. Major Depressive Disorder Market Drivers
19. Major Depressive Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Major Depressive Disorder Market report here: https://www.delveinsight.com/report-store/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us:

Kritika Rehani
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.